Ameriprise
AMLX icon

Ameriprise’s Amylyx Pharmaceuticals AMLX Stock Holding History

Ameriprise’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.25M Buy
+125,484
New +$1.94M ﹤0.01% 3010
2026
Q1 		– Sell
-502,366
Closed -$6.07M – 4052
2025
Q4 		$6.07M Buy
502,366
+368,858
+276% +$5.01M ﹤0.01% 2302
2025
Q3 		$1.81M Buy
133,508
+38,289
+40% +$360K ﹤0.01% 3055
2025
Q2 		$610K Buy
95,219
+82,414
+644% +$401K ﹤0.01% 3456
2025
Q1 		$45.3K Sell
12,805
-37,623
-75% -$134K ﹤0.01% 3947
2024
Q4 		$191K Buy
+50,428
New +$237K ﹤0.01% 3878
2023
Q4 		– Sell
-129,918
Closed -$2.38M – 3898
2023
Q3 		$2.38M Sell
129,918
-254
-0.2% -$5.37K ﹤0.01% 2742
2023
Q2 		$2.81M Sell
130,172
-82,281
-39% -$2.22M ﹤0.01% 2703
2023
Q1 		$6.23M Buy
212,453
+8,377
+4% +$291K ﹤0.01% 2165
2022
Q4 		$7.54M Buy
204,076
+136,201
+201% +$4.83M ﹤0.01% 1987
2022
Q3 		$1.91M Sell
67,875
-31,080
-31% -$775K ﹤0.01% 2804
2022
Q2 		$1.91M Buy
98,955
+16,645
+20% +$198K ﹤0.01% 2830
2022
Q1 		$1.06M Buy
+82,310
New +$1.86M ﹤0.01% 3191

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Ameriprise's AMLX Position: Q2 2026 in Review

Ameriprise opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 125,484 shares worth $2.25M. The stake represents ﹤0.01% of the portfolio and ranks #3010 among its holdings. This is a return to the name: Ameriprise previously reported a position in AMLX as recently as Q4 2025.

Ameriprise first reported a position in AMLX in Q1 2022 and has held it in 13 quarters since. The position peaked at $7.54M in Q4 2022. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Ameriprise held 125,484 shares of Amylyx Pharmaceuticals worth $2.25M as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Ameriprise position in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3010 holding.
  • Ameriprise first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
  • Ameriprise's Amylyx Pharmaceuticals position peaked at $7.54M in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.